News
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults with plaque psoriasis who are candidates for systemic therapy or phototherapy.
Dupixent approved as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older.
Talazoparib is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer.
Patients with multiple sclerosis who began treatment with ocrelizumab 2 years earlier had significant reductions in 24-week confirmed disability progression compared to patients who switched from interferon beta-1a.
Inotersen is the first FDA-approved RNA-targeting therapeutic that reduces production of the transthyretin protein through a once-weekly subcutaneous injection.
About the Specialty Pharmacy Times Industry Guide
The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees.
The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.
